New hope for tough bladder cancers: trial tests Next-Generation treatments
NCT ID NCT05562830
Summary
This study is testing new drug combinations for people with advanced bladder cancer that has stopped responding to standard immunotherapy. It will enroll 48 participants whose cancer has progressed despite previous treatment. The trial aims to find new options to control the disease by testing investigational drugs, some given with the immunotherapy drug pembrolizumab.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anschutz Cancer Pavilion ( Site 1017)
Aurora, Colorado, 80045, United States
-
Asan Medical Center ( Site 1901)
Seoul, 05505, South Korea
-
Bradford Hill ( Site 1155)
Santiago, Region M. de Santiago, 8420383, Chile
-
Cleveland Clinic-Taussig Cancer Center ( Site 1036)
Cleveland, Ohio, 44195, United States
-
FALP-UIDO ( Site 1151)
Santiago, Region M. de Santiago, 7500921, Chile
-
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1408)
Milan, Lombardy, 20133, Italy
-
Hospital Clinico San Carlos ( Site 1765)
Madrid, 28040, Spain
-
Hospital Universitari Vall d'Hebron ( Site 1767)
Barcelona, Catalonia, 08035, Spain
-
Huntsman Cancer Institute ( Site 1041)
Salt Lake City, Utah, 84112-5500, United States
-
Indiana University Melvin and Bren Simon Cancer Center ( Site 1011)
Indianapolis, Indiana, 46202, United States
-
Istituto Nazionale Tumori IRCCS Fondazione Pascale-S.C. Sperimentazioni Cliniche ( Site 1406)
Naples, 80131, Italy
-
Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL)-medical oncology ( Site 1302)
Amsterdam, North Holland, 1066 CX, Netherlands
-
Princess Margaret Cancer Centre ( Site 1106)
Toronto, Ontario, M5G 2M9, Canada
-
ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 1201)
London, London, City of, SW3 6JJ, United Kingdom
-
Rabin Medical Center-Oncology ( Site 1504)
Petah Tikva, 4941492, Israel
-
Rambam Health Care Campus-Oncology ( Site 1501)
Haifa, 3109601, Israel
-
Rigshospitalet-Dept. of Oncology ( Site 1701)
Copenhagen, Capital Region, 2100, Denmark
-
Royal Brisbane and Women's Hospital-Medical Oncology Clinical Trials Unit, Cancer Care Services ( Site 1952)
Brisbane, Queensland, 4029, Australia
-
Samsung Medical Center ( Site 1902)
Seoul, 06351, South Korea
-
Severance Hospital, Yonsei University Health System ( Site 1903)
Seoul, 03722, South Korea
-
Sheba Medical Center-ONCOLOGY ( Site 1503)
Ramat Gan, 5265601, Israel
-
Siteman Cancer Center ( Site 1038)
St Louis, Missouri, 63108, United States
-
St Bartholomew's Hospital ( Site 1206)
London, London, City of, EC1A 7BE, United Kingdom
-
UPMC Hillman Cancer Center ( Site 1014)
Pittsburgh, Pennsylvania, 15232, United States
-
University of California San Francisco ( Site 1044)
San Francisco, California, 94158, United States
-
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 1045)
Orange, California, 92868, United States
-
University of Chicago Medical Center ( Site 1037)
Chicago, Illinois, 60637, United States
Conditions
Explore the condition pages connected to this study.